Skip to main content

Health condition

Anaphylaxis in mastocytosis and MCAS, from tryptase and KIT testing to venom immunotherapy and TKIs.

A clonal mast cell disorder, or a syndrome of episodic mediator release. Both need a structured workup, an adrenaline plan, and a specialist team.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Editorial team

    Written by our editorial team from the UK sources listed on each page.

  • 02

    Sourced from guidance

    Checked against BSACI, WHO, ECNM and European Competence Network on Mastocytosis standards.

  • 03

    Current for 2026

    Reflects modern UK practice including KIT D816V testing, avapritinib and lifelong venom immunotherapy in mastocytosis.

Key facts

Mastocytosis and MCAS at a glance.

The essentials, in plain English: what these disorders are, how they cause anaphylaxis, and how they are diagnosed and treated in UK practice.

  • What it is

    A clonal mast cell disorder (systemic or cutaneous mastocytosis) or mast cell activation syndrome (MCAS) with episodic mediator release causing anaphylaxis.

  • Genetic driver

    Around 90% of adults with systemic mastocytosis carry the somatic KIT D816V mutation, testable by high-sensitivity PCR on peripheral blood.

  • Anaphylaxis burden

    Roughly 30 to 50% of adults with systemic mastocytosis have anaphylaxis, often severe, hypotensive and without urticaria.

  • Common triggers

    Hymenoptera venom (wasp, bee), opioids, NSAIDs, general anaesthetic agents, alcohol, heat, exercise, and food, though many episodes are idiopathic.

  • Diagnostic anchor

    Serum tryptase: a baseline above 11.4 ng/mL raises suspicion; an acute rise of 20% + 2 ng/mL above baseline supports mast cell activation.

  • Adrenaline is essential

    Two adrenaline auto-injectors, a written emergency plan and a medical alert are non-negotiable for anyone with mastocytosis-related anaphylaxis.

Why this guide matters

Three things to separate mastocytosis from ordinary allergy.

Anaphylaxis with mastocytosis behaves differently from IgE-mediated allergy. Recognising it changes tests, drugs and long-term plan.

  • Tryptase is the anchor test

    A baseline tryptase above 11.4 ng/mL, or an acute rise of 20% + 2 ng/mL from baseline, is the single most useful bedside test in this space.

  • KIT D816V changes the diagnosis

    Around 90% of adults with systemic mastocytosis carry the somatic KIT D816V mutation, testable on peripheral blood by high-sensitivity PCR.

  • Venom immunotherapy is lifelong

    Standard 3 to 5 year VIT is not enough in mastocytosis - the risk of recurrent and fatal reactions makes lifelong VIT the UK standard of care.

How the diagnosis is made

From first reaction to a confirmed diagnosis.

The steps a UK allergy, dermatology or haematology team will normally follow, in order, so you know what to expect and why.

  1. 01

    Assessing

    Clinical history and pattern

    Episodic flushing, hypotension, syncope, GI cramping, urticaria or angio-oedema, mapped against triggers, timing and severity.

  2. 02

    Assessing

    Baseline serum tryptase

    Drawn when well: above 11.4 ng/mL raises suspicion of clonal mast cell disease; persistently high values warrant KIT testing.

  3. 03

    Assessing

    Event-related tryptase

    Sample within 15 minutes to 3 hours of a reaction, then repeat baseline: a rise of 20% + 2 ng/mL supports mast cell activation (MCAS criteria).

  4. 04

    Confirming

    KIT D816V mutation testing

    High-sensitivity peripheral blood PCR screens for systemic mastocytosis; a positive result is a REMA-score booster and referral trigger.

  5. 05

    Confirming

    Bone marrow biopsy

    Immunohistochemistry for CD117, CD25, tryptase and KIT D816V confirms WHO systemic mastocytosis and defines the subtype and burden.

  6. 06

    Confirming

    Skin and urinary studies

    Skin biopsy for urticaria pigmentosa or maculopapular cutaneous mastocytosis; 24-hour urinary N-methylhistamine and prostaglandin D2 metabolites where available.

  7. 07

    Excluding

    Exclude mimics and comorbidity

    Rule out carcinoid and phaeochromocytoma when flushing dominates; check TSH, coeliac serology and ferritin; arrange DEXA for osteoporosis risk.

Typical timeline: bloods and referral within weeks; bone marrow and full workup within months.

Symptoms

What mast cell disease actually looks like.

Episodic flushing, hypotension, urticaria, GI and neurocognitive symptoms - with red flag features that mean it is time to escalate.

  • Flushing and pruritus

    Sudden face, neck and chest flushing with itch, often the earliest warning of a mediator release episode.

  • Urticaria and angio-oedema

    Weals, lip or tongue swelling, or urticaria pigmentosa (fixed brown macules that wheal on rubbing, Darier sign positive).

  • Cardiovascular collapse

    Hypotension, presyncope or syncope, sometimes without any skin signs, especially with venom or drug triggers.

  • Respiratory features

    Bronchospasm, wheeze, throat tightness or stridor, driven by mast cell mediators and airway smooth muscle contraction.

  • Gastrointestinal cramping

    Nausea, vomiting, cramping pain and diarrhoea during episodes, sometimes the dominant complaint in MCAS.

  • Neurocognitive symptoms

    Brain fog, fatigue, headache and mood disturbance are common in mastocytosis and often underrecognised.

  • Bone pain and fragility

    Osteoporosis and vertebral fractures are common in adult systemic mastocytosis, warranting routine DEXA.

  • Red flag - hypotensive anaphylaxis

    Any hypotensive reaction without urticaria, or venom-triggered anaphylaxis, should prompt tryptase and KIT testing.

Treatment

How mastocytosis-related anaphylaxis is treated in the UK.

Trigger avoidance, layered mediator-directed medication, adrenaline, lifelong venom immunotherapy where indicated, and TKIs for advanced disease.

  • Trigger avoidance plan

    A personalised list covering hymenoptera venom, opioids, NSAIDs, alcohol, heat, exercise triggers and anaesthetic agents flagged for the anaesthetist.

  • H1 and H2 antihistamines

    Daily non-sedating H1 blocker (cetirizine, fexofenadine, bilastine) plus an H2 blocker (famotidine) as background mediator control.

  • Leukotriene antagonist

    Montelukast added when antihistamines alone do not settle flushing, cramping or exercise-related symptoms.

  • Mast cell stabilisers

    Oral sodium cromoglicate for GI-predominant disease; ophthalmic cromoglicate for ocular mast cell symptoms.

  • Adrenaline auto-injectors

    Two pen-injectors carried at all times, a written BSACI emergency plan and a medical alert bracelet or necklace.

  • Venom immunotherapy (VIT)

    Lifelong VIT is the standard of care for hymenoptera-triggered anaphylaxis in mastocytosis, given the higher risk of recurrent and fatal reactions.

  • Omalizumab (off-label)

    Anti-IgE monoclonal used off-label for refractory MCAS and mastocytosis-related anaphylaxis when antihistamines and cromoglicate are not enough.

  • Tyrosine kinase inhibitors

    Midostaurin (Rydapt) and avapritinib (Ayvakit) are approved in advanced systemic mastocytosis with high mast cell burden, with significant symptom and tryptase reduction.

What this guide is based on

The sources behind every claim on this page.

UK and international specialist society standards, current at the time of last review.

Key references

Guidelines and consensus criteria we relied on.

A quiet reminder

This guide is for information, not medical advice.

Mastocytosis and MCAS are specialist conditions. Any workup and treatment should be led by a UK allergy, dermatology or haematology team.

  • BSACI. Guidelines for the management of anaphylaxis and mastocytosis (UK).

  • World Health Organization. Classification of tumours of haematopoietic and lymphoid tissues - mastocytosis criteria.

  • European Competence Network on Mastocytosis (ECNM). Consensus statements on diagnosis and management.

  • Valent P et al. Global classification of mast cell activation disorders and consensus diagnostic criteria for MCAS.

  • NICE and MHRA. Guidance on avapritinib and midostaurin for advanced systemic mastocytosis.

Red flags

When to think mastocytosis, not just allergy.

Anaphylaxis with these features should trigger tryptase, KIT and specialist referral rather than a purely allergy-focused workup.

  • Hypotensive anaphylaxis without urticaria

    A classic presentation of mastocytosis-related anaphylaxis - always draw baseline and acute tryptase and refer to allergy or haematology.

  • Hymenoptera venom anaphylaxis

    Wasp or bee sting anaphylaxis in an adult carries a substantially higher chance of underlying clonal mast cell disease and warrants VIT.

  • Peri-anaesthetic anaphylaxis

    Any collapse under general anaesthetic in someone with mastocytosis needs a full drug reaction workup with the anaesthetic allergy service.

  • Persistent baseline tryptase above 11.4

    Warrants KIT D816V testing and referral - do not attribute to allergy alone; consider hereditary alpha-tryptasaemia and systemic mastocytosis.

  • Osteoporotic fracture in a young adult

    A low-trauma fracture in someone with unexplained flushing, itch or GI symptoms is a classic red flag for systemic mastocytosis.

  • Idiopathic anaphylaxis recurrence

    Two or more episodes of unexplained anaphylaxis should prompt tryptase, KIT and specialist mastocytosis review.

  • Opioid or NSAID reactions

    Non-IgE mediated mast cell degranulation is common in mastocytosis - all opioids and NSAIDs should be reviewed with a specialist.

  • Failure of standard antihistamines

    Persistent flushing, urticaria or GI symptoms despite maximal H1 and H2 blockade suggests clonal disease rather than simple allergy.

  • Systemic B or C findings

    Weight loss, hepatosplenomegaly, cytopenias or organ dysfunction may indicate advanced or aggressive systemic mastocytosis.

Living with it

A serious condition, a manageable plan.

Four everyday priorities that keep the risk of severe reactions low: an adrenaline kit, a trigger list, a specialist team, and bone protection.

A quiet reminder

Preparation, not fear, is the aim.

A written plan, two auto-injectors, a clear trigger list and a specialist team make daily life predictable and safe.

  1. 01 Plan

    Carry your kit, always

    Two adrenaline auto-injectors, antihistamines, your BSACI emergency plan and a medic alert - a non-negotiable daily routine.

  2. 02 Avoid

    Know your triggers

    A written trigger list (drugs, venom, heat, alcohol, exercise, foods) shared with GP, dentist and anaesthetist prevents avoidable reactions.

  3. 03 Team

    Use a specialist centre

    A referral to Guy and St Thomas UK Mastocytosis Centre or another ECNM-affiliated service brings modern testing and TKI access.

  4. 04 Bone

    Protect your bones

    Baseline DEXA, vitamin D, calcium and bisphosphonates where indicated - osteoporosis is common and treatable.

Frequently asked

Everything we get asked about mastocytosis and MCAS.

Quick answers on tryptase, KIT testing, venom immunotherapy and modern TKI options.

  • What is anaphylaxis in mastocytosis?

    It is a severe systemic allergic reaction driven by mast cell mediator release in someone with an underlying clonal mast cell disorder. Around 30 to 50% of adults with systemic mastocytosis experience anaphylaxis, often more severe and more likely to cause hypotension than allergic anaphylaxis in the general population.

  • How is MCAS different from mastocytosis?

    Mastocytosis is a clonal proliferation of abnormal mast cells (WHO-defined, KIT D816V driven). MCAS is a clinical syndrome of episodic mast cell mediator symptoms requiring three criteria: typical symptoms in two or more organ systems, a documented event-related rise in tryptase of 20% + 2 ng/mL above baseline, and response to mast cell mediator-directed therapy. Someone can have primary (clonal) MCAS on a background of mastocytosis, secondary MCAS driven by IgE allergy, or idiopathic MCAS.

  • What tests do I need?

    Baseline serum tryptase, an acute tryptase within 15 minutes to 3 hours of any reaction, KIT D816V mutation testing on peripheral blood, and referral for bone marrow biopsy with CD117, CD25, tryptase and KIT immunohistochemistry if systemic mastocytosis is suspected. Add skin biopsy for urticaria pigmentosa, DEXA, and, where relevant, urinary N-methylhistamine and prostaglandin D2 metabolites.

  • Do I need venom immunotherapy?

    If you have had anaphylaxis to a wasp or bee sting and have mastocytosis, the standard of care is lifelong venom immunotherapy. Untreated, the risk of recurrent and fatal reactions is significantly higher than in the general population, so most UK allergy services will not stop VIT after the usual 3 to 5 years.

  • What are avapritinib and midostaurin?

    They are tyrosine kinase inhibitors that target the KIT D816V mutation. Both are approved for advanced systemic mastocytosis with high mast cell burden and can produce substantial reductions in tryptase, symptoms and mast cell infiltration. Prescribing sits with specialist haematology and mastocytosis centres.

  • Should I avoid opioids and NSAIDs?

    Not automatically - but they are common non-IgE triggers of mast cell degranulation, so any use should be discussed with your specialist. Many patients tolerate paracetamol, fentanyl, and selective COX-2 inhibitors, but the plan should be individual and documented on your alert card and anaesthetic record.

Related content

Keep reading.